University of Hertfordshire

From the same journal

By the same authors

Secondary Neoplasms of the Urinary Bladder-Clinical Management and Oncological Outcomes

Research output: Contribution to journalArticlepeer-review


  • Omar El-Taji
  • Abdullah Al-Mitwalli
  • Farhan Malik
  • Samita Agarwal
  • Andrew Gogbashian
  • Rob Hughes
  • Nikhil Vasdev
  • Anand Sharma
View graph of relations
Original languageEnglish
Number of pages10
JournalTranslational Andrology and Urology
Publication statusPublished - 1 Jun 2021


Background: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current literature with long term oncological follow up.

Methods: This is a single institutional, retrospective cohort study of patients with a histological diagnosis of a secondary bladder neoplasm from January 2007 to December 2017 (n=40). Prognostic variables examined included age at diagnosis, histology, disease free survival and treatment. Kaplan-Meier analysis was used to calculate survival. We used multiple regression analysis to identify the most significant treatments for each population group in terms of their survival.

Results: Twenty-one patients were male (53%) with a median age of 68 and 19 were female (47%) with a median age of 64. The most common secondary neoplasms and their median survival were prostate [12 patients (30%), 446 days], colorectal [9 patients (23%), 403 days], ovarian [5 patients (13%), 369 days], cervical [4 patients (10%), 148 days], breast [3 patients (8%), 241 days], lymphoma [3 patients (8%), 145 days], gastric [2 patients (5%), 66 days], and renal [2 patients (5%), 854 days]. Those receiving treatment following a secondary diagnosis demonstrated statistical significance in survival for colorectal (surgery P=0.013), prostate (radiotherapy P=0.0012 and hormonal therapy P=0.004) and ovarian cancer (chemotherapy P=0.00002).

Conclusions: Prognosis and treatment depends upon the primary neoplasm. There is some survival benefit in well selected patients receiving treatment following a diagnosis of a bladder secondary.


© Translational Andrology and Urology. All rights reserved. This is an Open Access article distributed in accordance with the Creative Commons Attribution-Non Commercial-No Derivate 4.0 International License (CC BY-NC-ND 4.0), See:

ID: 24118297